All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
A Randomized Phase II Trial Of Triplet Therapy (A Pd-L1 Inhibitor Durvalumab (Medi4736) In Combination With Olaparib And Cediranib) Compared To Olaparib And Cediranib Or Durvalumab (Medi4736) And Cediranib Or Standard Of Care Chemotherapy In Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Or Fallopian Cancer Who Have Received Prior Bevacizumab
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
recurrent or persistent Uterine Serous Carcinoma (USC)
GOG-3059 - A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer.
A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
Phase I, First In Human Trial Evaluating BI 1387446 Alone And In Combination with BI 754091 in Solid Tumors
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
A Phase 2 Study of PacritiniB for Patients with BiochemicaL RelApse after Definitive Treatment for ProStaTe Cancer
Researchers would also like to study how Pacritinib slows down the time until cancer
progression and assess its safety and tolerability.